Telix Pharmaceuticals files registration statement for proposed U.S. IPO

Telix Pharmaceuticals has filed a registration statement on Form F-1 with the United States Securities and Exchange Commission relating to a proposed initial public offering of its American Depository Shares, representing the Company’s ordinary shares, in the U.S. Telix has applied to list the ADSs on the Nasdaq Global Market under the symbol “TLX”. The number of ordinary shares to be represented by each ADS, the number of ADSs to be offered and the price per ADS for the proposed Offering have not yet been determined. The Offering is subject to market conditions, and there can be no assurance as to whether or when the Offering may be completed. Jefferies, Morgan Stanley, Truist Securities and William Blair will act as joint book-running managers for the proposed Offering.